Prof Massimo Cristofanilli speaks with ecancer at ESMO 2018 in Munich about the analysis of data from the PALOMA-3 study of palbociclib with fulvestrant to treat HR /HER2- breast cancer, following the previous publication of PFS data.
He outlines the importance of prior sensitisation with endocrine therapy in this population, and recommends the combination as a new standard of care.
For more on this trial, watch his presentation of data at a conference session here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.